New research suggests that while new medical guidelines and increased public awareness of problems with the use of opioids to treat chronic pain may be helping to slow the number of new opioid users, the prevalence of disorders, frequency of use and deaths linked to prescription opioids is rising.
At the same time, the percentage of nonmedical use of prescription opioids decreased among adults in the U.S., according to the study that looked at data for the years 20013 to 2013. The study was published by JAMA, the journal of the American Medical Association, in its October 13 issue.
From 2003 to 2013, the percentage of nonmedical use of prescription opioids decreased among adults in the U.S., while the prevalence of prescription opioid use disorders, frequency of use, and related deaths increased, according to a study in the October 13 issue of JAMA.
Since 1999, the United States has experienced increases in illness and death associated with nonmedical use of prescription opioids, which is being called a U.S. epidemic. During this period, emergency department visits and drug overdose deaths involving these drugs have increased rapidly.
The study’s authors said that an examination of nationally representative U.S. surveillance data is needed in order to fully understand the current status of the epidemic and who is currently most affected.
Beth Han, M.D., Ph.D., M.P.H., of the Substance Abuse and Mental Health Services Administration, Rockville, Md., and colleagues examined the prevalence of nonmedical use and use disorders (dependence on or abuse of alcohol, marijuana, cocaine, hallucinogens, heroin, inhalants, or nonmedical use of prescription pain relievers, sedatives, or stimulants) and related risk factors with data from 472,200 persons who participated in the 2003-2013 National Surveys on Drug Use and Health. Mortality was based on the 2003-2013 National Vital Statistics System’s Multiple Cause of Death Files.
Among adults age 18 through 64 years, the prevalence of nonmedical use of prescription opioids decreased from 5.4 percent in 2003 to 4.9 percent in 2013, but the prevalence of prescription opioid use disorders increased from 0.6 percent in 2003 to 0.9 percent in 2013. The 12-month prevalence of high-frequency use (200 days or more) also increased from 0.3 percent in 2003 to 0.4 percent in 2013.
Mortality assessed by drug overdose death rates involving prescription opioids increased from 4.5 per 100,000 in 2003 to 7.8 per 100,000 in 2013. The average number of days of nonmedical use of prescription opioids increased from 2.1 in 2003 to 2.6 in 2013. The prevalence of having prescription opioid use disorders among nonmedical users increased to 15.7 percent in 2010, 16.1 percent in 2011, 17 percent in 2012, and 16.9 percent in 2013, from 12.7 percent in 2003.
The researchers said they found a “significant decrease in the percentage of nonmedical use of prescription opioids, as well as significant increases in the prevalence of prescription opioid use disorders, high-frequency use, and related mortality” among adults aged 18 through 64 years in the United States over the past decade.
The authors said the increases identified in their study occurred in the context of increasing heroin use and heroin-related overdose deaths in the United States, “supporting a need to address nonmedical use of prescription opioid and heroin abuse in a coordinated and comprehensive manner.”
The authors say treatment for substance use disorders is critical yet most adults with prescription opioid use disorders or other substance use disorders neither receive treatment nor do they perceive a need for treatment. In 2013, more than three-fourths of adults aged 18 through 64 years who had prescription opioid use disorders did not receive any substance use treatment, according to the report. The authors say that policy and societal barriers prevent broad adoption of medication-assisted therapies for people with prescription opioid use disorders.
In an accompanying editorial, JAMA cites multiple factors as possible explanations for the decrease in new opioid users. The editorial says the likely factors may include the use of prescribing guidelines for chronic pain, rationalizing expectations of physicians and patients for pain control and functional outcome, media attention on the consequences of addiction, and regulatory and legal efforts.
“It is encouraging that the culture around prescription opioids is starting to change, especially when considering the marketing of a plethora of new opioids for the treatment of chronic pain, none of which has been shown to be safe and effective over the long term,” writes Lewis S. Nelson, M.D., of the New York University School of Medicine, and colleagues, in JAMA’s editorial.
“The chronic, relapsing nature of opioid addiction means most patients are never ‘cured’ and the best outcome is long-term recovery. The lifelong implications of this disease far outweigh the limited benefits of opioids in the treatment of chronic pain, and in many cases the risks inherent in the treatment of acute pain with opioids. The encouraging finding of declining opioid initiation rates should be tempered by the increasing rates of nonmedical opioid use disorders and the limited utilization of treatment programs. Although multifaceted approaches are needed to successfully address the opioid epidemic, an important step is to start at the beginning and keep opioid-naive patients opioid naive,” the editorial says.
Was this article valuable?
Here are more articles you may enjoy.